Published in Cancer Weekly, June 10th, 2003
The news sent the biotechnology company's stock soaring nearly 45% and boosted the spirits of researchers working with similar drugs in a field plagued by recent setbacks.
Genentech's Avastin is the most advanced drug in this new class of medicines, which are intended to choke off the blood supply to cancer tumors. The work was pioneered by Dr. Judah Folkman some 30 years ago.
"The fact that this extended life is a very major medical breakthrough,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.